Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine
- 1 February 2001
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 8 (4) , 332-339
- https://doi.org/10.1038/sj.gt.3301392
Abstract
At the forefront of medicine, Gene Therapy brings you the latest research into genetic and cell-based technologies to treat disease. It also publishes Progress & Prospects reviews and News and Commentary articles, which highlight the cutting edge of the field.Keywords
This publication has 35 references indexed in Scilit:
- Tumor Growth Inhibition by Intratumoral Inoculation of Defective Herpes Simplex Virus Vectors Expressing Granulocyte–Macrophage Colony-Stimulating FactorMolecular Therapy, 2000
- Treatment of Human Breast Cancer in a Brain Metastatic Model by G207, a Replication-Competent Multimutated Herpes Simplex Virus 1Human Gene Therapy, 1998
- Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon.Journal of Clinical Investigation, 1997
- Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor AntigensScience, 1994
- Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?Immunology Today, 1994
- IL-12: Initiation Cytokine for Cell-Mediated ImmunityScience, 1993
- Expression of a functional foreign gene in adult mammalian brain following in Vivo transfer via a herpes simplex virus type 1 defective viral vectorMolecular and Cellular Neuroscience, 1991
- GanciclovirDrugs, 1990
- Abnormal Forms of the Herpes Simplex Virus Immediate Early Polypeptide Vmw175 Induce the Cellular Stress ResponseJournal of General Virology, 1987
- Determination of the Sequence Alteration in the DNA of the Herpes Simplex Virus Type 1 Temperature-sensitive Mutant ts KJournal of General Virology, 1984